Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
Study of TG-1701 an Irreversible Bruton's Tyrosine Kinase Inhibitor in Patients With B-Cell Malignancies

This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies

lymphoma
b-cell lymphoma
tyrosine
cancer
  • 117 views
  • 26 Jul, 2021
  • 16 locations
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is

idelalisib
chronic lymphocytic leukemia
neutrophil count
btk inhibitor
bendamustine
  • 0 views
  • 04 Jul, 2021
  • 97 locations
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell

hepatitis b surface antigen
measurable disease
follicular lymphoma
btk inhibitor
mantle cell lymphoma
  • 7 views
  • 01 Aug, 2021
  • 8 locations
A Study of ICP-022 in Patients With R/R DLBCL

It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL. There

btk inhibitor
b-cell lymphoma
  • 0 views
  • 01 Aug, 2021
  • 6 locations
Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will

cold agglutinin
cytopenia
dexamethasone
lymphoma
fludarabine
  • 0 views
  • 24 Jan, 2021
  • 1 location
Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma MCL MATCH Trial

them not respond to a certain type of drug called a Bruton's tyrosine kinase (BTK) inhibitor. The goal of this clinical research study is to use genetic testing to identify which drugs may be most

  • 0 views
  • 14 May, 2021
  • 1 location
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor

flow cytometry
measurable disease
anthracyclines
btk inhibitor
rituximab
  • 1 views
  • 24 Jan, 2021
  • 1 location
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK

g-csf
corticosteroids
monoclonal antibodies
btk inhibitor
lymphoid leukemia
  • 0 views
  • 29 Mar, 2021
  • 1 location
Ibrutinib Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

employ three target therapy drugs in sequencing phases. It will start with a BTK inhibitor as induction, later an anti-CD20 will be used for consolidation and it will end with a BH3 analog as maintenance

ibrutinib
TP53
obinutuzumab
residual tumor
btk inhibitor
  • 0 views
  • 23 Jan, 2021
  • 2 locations
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

is considered experimental. Experimental means that it is still being tested to see if it is safe and effective. Ibrutinib is a new drug known as a 'Bruton's Tyrosine Kinase (BTK) inhibitor

ibrutinib
measurable disease
lymphocytic leukemia
hematologic malignancy
mantle cell lymphoma
  • 88 views
  • 15 Mar, 2021
  • 1 location